Study summary
Darovasertib plus crizotinib more than doubled time before growth
37.1%of tumors shrank, vs 5.8% with doctor's choice
What was tested
Darovasertib, a pill that blocks PKC, with crizotinib, against doctor's choice, as first treatment for metastatic uveal melanoma in people without the HLA-A*02:01 tissue type, who cannot receive tebentafusp.
What they found
- Median time before growth was 6.9 vs 3.1 months.
- Tumors shrank in 37.1% vs 5.8%.
- Survival results were also reported as favorable.
What it means
Likely the first approved drug for the half of patients who cannot get tebentafusp. The companies planned an FDA filing in the second half of 2026.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.